GSK's 'all in' vax investment

GSK has gone all-in on mRNA vaccines for influenza and COVID-19, taking full control of its collaboration with German biotech CureVac.

The two companies began collaborating on mRNA in 2020, and signed a deal on Covid in particular in 2021, which included a 75 million euro (AU$120 million) upfront payment, with the vaccines targeted for availability in 2022.

The vaccines for seasonal influenza and Covid are still in Phase 2 trials, but GSK maintains faith in the technology, saying the trial data is promising and demonstrates potential for best-in-class vaccines.